Techonomy reaches thousands every week in email and on LinkedIn with an insightful newsletter not just highlighting the week’s technology coverage on Worth but also probing the the bigger picture behind these stories. (Read on LinkedIn.)… Read the rest
Decades later, the environmental damage has met our dimmest expectations, but some of the progress has met our brightest hopes. (Read on Worth)… Read the rest
On climate and consumption, we’ve long thought that tech would let us have our cake and eat it too. That’s looking less certain. (Read on Worth)… Read the rest
Efforts are afoot to extend healthy lives, but doing it in a way that benefits everyone equally is still a challenge. (Read on Worth magazine)… Read the rest
No end is in sight, and the politics are becoming more dire. But courageous people inside and outside Ukraine are striving to sustain the nation and its people. (Read on Worth)… Read the rest
Long speculated to slow or even reverse aging in off-label use, the generic drugs metformin and rapamycin are getting formal clinical trials this year. (Worth magazine)… Read the rest
A one-time climate helper is becoming the biggest threat, due to runaway growth and climate-warming methane emissions. (Read on Worth)… Read the rest
The Paris Agreement has failed. But tech and innovation can soften the blow of a warming climate and still help prevent the worst-case scenarios. (Read on Worth)… Read the rest
